











Dose Response Curves

Report Date:October 09, 2012

Test Date:March 26, 2012

All Cell Lines





National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

NSC : 763857 / 1	Experiment ID : 1203NS37	Test Type : 08	Units : Molar
Report Date : October 09, 2012	Test Date : March 26, 2012	QNS :	MC :
COMI : A2298/0096839 (114516)	Stain Reagent : SRB Dual-Pass Related	SSPL : 0YAR	

Panel/Cell Line	Log10 Concentration												GI50	TGI	LC50
	Time Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.709	2.591	2.498	2.432	1.894	1.091	0.421	95	92	63	20	-41	2.01E-6	2.15E-5	> 1.00E-4
HL-60(TB)	0.902	2.813	2.835	2.872	1.899	0.589	0.379	101	103	52	-35	-58	1.06E-6	3.99E-6	4.52E-5
K-562	0.273	1.722	1.845	1.829	0.654	0.464	0.097	108	107	26	13	-65	5.10E-7	1.48E-5	6.48E-5
MOLT-4	0.728	2.501	2.481	2.563	2.049	1.073	0.471	99	103	74	19	-35	2.78E-6	2.27E-5	> 1.00E-4
RPMI-8226	0.911	2.482	2.374	2.408	2.266	1.392	1.170	93	95	86	31	16	4.48E-6	> 1.00E-4	> 1.00E-4
SR	0.453	1.480	1.482	1.546	0.610	0.244	0.083	100	106	15	-46	-82	4.16E-7	1.77E-6	1.28E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.256	1.279	1.231	1.195	0.579	0.087	0.155	95	92	32	-66	-40	4.94E-7	2.11E-6	.
HOP-62	0.332	0.959	0.988	0.969	0.760	0.207	0.157	105	102	68	-38	-53	1.49E-6	4.40E-6	6.46E-5
HOP-92	1.339	1.625	1.559	1.529	1.466	1.201	0.593	77	66	44	-10	-56	5.57E-7	6.48E-6	7.47E-5
NCI-H226	0.563	1.132	1.117	1.139	1.080	0.161	0.306	97	101	91	-71	-46	1.79E-6	3.63E-6	.
NCI-H23	0.598	1.787	1.761	1.675	1.420	1.050	0.650	98	91	69	38	4	4.12E-6	> 1.00E-4	> 1.00E-4
NCI-H322M	0.849	1.655	1.811	1.763	1.660	0.920	1.015	119	113	101	9	21	3.56E-6	> 1.00E-4	> 1.00E-4
NCI-H460	0.255	2.241	2.292	2.290	1.701	0.175	0.180	103	102	73	-31	-30	1.66E-6	5.00E-6	> 1.00E-4
Colon Cancer															
COLO 205	0.321	1.115	1.190	1.186	0.882	0.362	0.520	110	109	71	5	25	2.06E-6	> 1.00E-4	> 1.00E-4
HCC-2998	0.364	1.062	1.011	1.079	0.888	0.621	0.656	93	102	75	37	42	4.53E-6	> 1.00E-4	> 1.00E-4
HCT-116	0.227	1.828	1.743	1.661	0.848	0.088	0.106	95	90	39	-61	-54	6.02E-7	2.44E-6	7.72E-6
HCT-15	0.311	1.839	1.869	1.810	0.933	0.392	0.571	102	98	41	5	17	6.89E-7	> 1.00E-4	> 1.00E-4
HT29	0.223	1.179	1.289	1.245	0.480	0.187	0.211	111	107	27	-16	-6	5.14E-7	4.21E-6	> 1.00E-4
KM12	0.443	2.059	2.142	2.112	1.298	0.431	0.633	105	103	53	-3	12	1.13E-6	.	> 1.00E-4
SW-620	0.288	1.867	1.842	1.789	0.807	0.425	0.462	98	95	33	9	11	5.30E-7	> 1.00E-4	> 1.00E-4
CNS Cancer															
SF-268	0.605	1.795	1.828	1.827	1.492	1.127	0.634	103	103	75	44	2	6.32E-6	> 1.00E-4	> 1.00E-4
SF-295	0.963	2.480	2.315	2.239	1.781	0.762	0.554	89	84	54	-21	-43	1.13E-6	5.25E-6	> 1.00E-4
SF-539	0.954	2.368	2.354	2.333	2.167	1.291	1.061	99	98	86	24	8	3.78E-6	> 1.00E-4	> 1.00E-4
SNB-75	0.687	1.279	1.130	1.161	0.965	0.162	0.234	75	80	47	-76	-66	8.04E-7	2.40E-6	6.11E-6
U251	0.326	1.552	1.470	1.419	1.164	0.157	0.140	93	89	68	-52	-57	1.42E-6	3.70E-6	9.63E-6
Melanoma															
LOX IMVI	0.300	1.933	1.933	1.870	1.233	0.361	0.358	100	96	57	4	4	1.36E-6	> 1.00E-4	> 1.00E-4
MALME-3M	0.686	1.235	1.231	1.211	0.917	0.864	0.576	99	96	42	32	-16	7.09E-7	4.66E-5	> 1.00E-4
M14	0.454	1.519	1.418	1.356	0.909	0.724	0.575	90	85	43	25	11	6.70E-7	> 1.00E-4	> 1.00E-4
MDA-MB-435	0.461	1.939	1.848	1.733	0.434	0.281	0.269	94	86	-6	-39	-42	2.47E-7	8.64E-7	> 1.00E-4
SK-MEL-28	0.371	0.947	0.931	0.885	0.721	0.568	0.719	97	89	61	34	60	.	> 1.00E-4	> 1.00E-4
SK-MEL-5	0.681	2.376	2.322	2.314	1.807	0.642	0.768	97	96	66	-6	5	1.69E-6	.	> 1.00E-4
UACC-257	0.558	1.276	1.245	1.174	0.996	0.905	0.805	96	86	61	48	34	7.32E-6	> 1.00E-4	> 1.00E-4
UACC-62	0.917	2.069	2.074	2.104	1.614	1.157	0.936	100	103	60	21	2	1.84E-6	> 1.00E-4	> 1.00E-4
Ovarian Cancer															
IGROV1	0.652	1.819	1.864	1.895	1.515	0.832	0.588	104	106	74	15	-10	2.56E-6	4.08E-5	> 1.00E-4
OVCAR-3	0.521	1.518	1.552	1.572	1.101	0.070	0.167	103	105	58	-87	-68	1.14E-6	2.52E-6	5.59E-6
OVCAR-4	0.418	0.805	0.771	0.770	0.478	0.077	0.156	91	91	15	-82	-63	3.49E-7	1.44E-6	4.72E-6
OVCAR-5	0.453	1.265	1.267	1.220	1.147	0.576	0.760	100	94	85	15	38	3.19E-6	> 1.00E-4	> 1.00E-4
OVCAR-8	0.282	1.292	1.243	1.226	0.890	0.460	0.417	95	93	60	18	13	1.74E-6	> 1.00E-4	> 1.00E-4
NCI/ADR-RES	0.393	1.438	1.413	1.366	0.615	0.278	0.295	98	93	21	-29	-25	3.98E-7	2.63E-6	> 1.00E-4
SK-OV-3	0.531	1.039	1.069	1.056	1.008	0.080	0.102	106	103	94	-85	-81	1.76E-6	3.35E-6	6.37E-6
Renal Cancer															
786-0	0.774	2.304	2.297	2.241	2.102	0.284	0.344	100	96	87	-63	-56	1.76E-6	3.79E-6	8.15E-6
A498	1.111	1.654	1.575	1.556	1.383	0.593	0.846	85	82	50	-47	-24	1.00E-6	3.29E-6	> 1.00E-4
ACHN	0.344	1.396	1.461	1.424	1.274	0.124	0.202	106	103	88	-64	-41	1.79E-6	3.80E-6	.
CAKI-1	0.809	2.242	2.168	2.071	1.551	0.785	0.980	95	88	52	-3	12	1.08E-6	.	> 1.00E-4
RXF 393	0.682	1.140	1.138	1.133	1.009	0.207	0.145	99	98	71	-70	-79	1.41E-6	3.20E-6	7.25E-6
SN12C	0.545	1.858	1.899	1.933	1.647	0.549	0.746	103	106	84	.	15	2.54E-6	> 1.00E-4	> 1.00E-4
UO-31	0.897	2.007	1.977	1.948	1.871	0.621	0.936	97	95	88	-31	4	2.08E-6	.	> 1.00E-4
Prostate Cancer															
PC-3	0.466	1.729	1.723	1.662	1.366	0.724	0.837	100	95	71	20	29	2.62E-6	> 1.00E-4	> 1.00E-4
DU-145	0.365	1.395	1.466	1.446	1.164	0.837	0.659	107	105	78	46	28	7.38E-6	> 1.00E-4	> 1.00E-4
Breast Cancer															
MCF7	0.330	1.792	1.655	1.588	0.692	0.442	0.545	91	86	25	8	15	3.87E-7	> 1.00E-4	> 1.00E-4
MDA-MB-231/ATCC	0.599	1.152	1.236	1.266	1.138	0.512	0.461	115	121	98	-15	-23	2.66E-6	7.42E-6	> 1.00E-4
HS 578T	0.853	1.481	1.451	1.366	1.257	0.914	0.759	95	82	64	10	-11	1.83E-6	2.94E-5	> 1.00E-4
BT-549	0.908	1.787	1.683	1.638	1.512	1.162	0.797	88	83	69	29	-12	2.94E-6	5.04E-5	> 1.00E-4
T-47D	0.558	1.241	1.233	1.203	1.038	0.407	0.495	99	94	70	-27	-11	1.61E-6	5.26E-6	> 1.00E-4
MDA-MB-468	0.551	1.309	1.281	1.267	0.802	0.284	0.194	96	94	33	-48	-65	5.29E-7	2.54E-6	1.24E-5

Mean Graphs

Report Date :October 09, 2012

Test Date :March 26, 2012

